Tirzepatide
SURMOUNT-J
Eli Lilly · Phase 3 · Completed · Enrollment 267
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 10 Milligrams (mg) Tirzepatide | n/r | n/r | n/r | n/r |
| 15 mg Tirzepatide | 96.05% | 92.11% | 82.89% | n/r |
| Placebo | 20% | 4% | 1.33% | n/r |
| 10 mg Tirzepatide | 94.37% | 85.92% | 63.38% | n/r |
Not shown
- 10 Milligrams (mg) Tirzepatide: endpoint not reported